Korean
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

oxalis pes-caprae/fatigue

링크가 클립 보드에 저장됩니다.
12 결과

Extended fatigue life of a catalyst free self-healing acrylic bone cement using microencapsulated 2-octyl cyanoacrylate.

등록 된 사용자 만 기사를 번역 할 수 있습니다.
로그인 / 가입
The tissue adhesive 2-octyl cyanoacrylate (OCA) was encapsulated in polyurethane microshells and incorporated into bone cement to form a catalyst free, self-healing bone cement comprised of all clinically approved components. The bending strength, modulus, and fatigue lifetime were investigated in
Primary biliary cholangitis (PBC) occurs as a result of immune-mediated damage to bile ducts, with an associated inflammatory response leading to progressive fibrosis and loss of patency. This loss of patency leads, in turn, to hepatic accumulation of bile acids, resulting in liver damage with

Current and promising therapy for primary biliary cholangitis.

등록 된 사용자 만 기사를 번역 할 수 있습니다.
로그인 / 가입
Primary biliary cholangitis is a chronic, cholestatic liver disease that may progress to cirrhosis with complications of end-stage liver disease. Approved treatment options include ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) but novel therapies are being

[Immune-mediated cholangiopathies : Diagnostic and therapeutic challenges].

등록 된 사용자 만 기사를 번역 할 수 있습니다.
로그인 / 가입
Immune-mediated cholangiopathies comprise primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and IgG4-associated cholangitis (IAC). A common feature is the progressive destruction of bile ducts leading to cholestasis with fibrosis and cirrhosis of the liver over

[Primary biliary cholangitis-established and novel therapies].

등록 된 사용자 만 기사를 번역 할 수 있습니다.
로그인 / 가입
Patients with primary biliary cholangitis (PBC, formerly primary biliary cirrhosis) and insufficient treatment response or risk factors exhibit a remarkably increased risk for disease progression and associated complications. Furthermore, extrahepatic manifestations may considerably reduce quality

What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?

등록 된 사용자 만 기사를 번역 할 수 있습니다.
로그인 / 가입
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by chronic cholestasis. Treatment with the accepted primary therapy ursodeoxycholic acid (UDCA) has been shown to be associated with delayed disease progression probably through reduced impact of cholestatic injury on

Clinical Management of Primary Biliary Cholangitis-Strategies and Evolving Trends.

등록 된 사용자 만 기사를 번역 할 수 있습니다.
로그인 / 가입
PBC is a chronic progressive autoimmune disorder involving the destruction of intrahepatic small bile ducts, cholestasis, fibrosis, and ultimately cirrhosis if left untreated. It is largely driven by the autoimmune response, but bile acids and the intestinal microbiota are implicated in disease

Trial of Essiac to ascertain its effect in women with breast cancer (TEA-BC).

등록 된 사용자 만 기사를 번역 할 수 있습니다.
로그인 / 가입
BACKGROUND Breast cancer is a major cause of morbidity, mortality, and medical expenditures among women in Canada. Essiac (Resperin Canada Limited, Waterloo, Ontario, Canada), a blend of at least four herbs (burdock root [Arctium lappa], Indian rhubarb [Rheum palmatum], sheep sorrel [Rumex

Update on Emerging Treatment Options for Primary Biliary Cholangitis

등록 된 사용자 만 기사를 번역 할 수 있습니다.
로그인 / 가입
Primary biliary cholangitis (PBC) is a rare autoimmune cholestatic liver disease that may progress to fibrosis or cirrhosis. Treatment options are currently limited. Ursodeoxycholic acid (UDCA) remains first-line therapy and has been proven to normalize serum biochemistries, halt histologic disease

Nanohybrid and microfilled hybrid versus conventional hybrid composite restorations: 5-year clinical wear performance.

등록 된 사용자 만 기사를 번역 할 수 있습니다.
로그인 / 가입
The 5-year findings of a randomized clinical trial testing the null hypothesis that there are no differences between the clinical-wear performances of nano-, microfilled-, and conventional hybrids placed in class I and class II cavities are reported. Effects of subject-, operator-, and

Effects of cyclic loading on occlusal contact area wear of composite restoratives.

등록 된 사용자 만 기사를 번역 할 수 있습니다.
로그인 / 가입
OBJECTIVE To investigate the effects of cyclic loading on occlusal contact area (OCA) wear and the possible presence of fatigue wear mechanisms in four composite resins (Silux, Z100, Ariston and Surefil) using a reciprocal compression-sliding test apparatus. METHODS Six specimens were made for each

Three-year randomized clinical trial to evaluate the clinical performance and wear of a nanocomposite versus a hybrid composite.

등록 된 사용자 만 기사를 번역 할 수 있습니다.
로그인 / 가입
OBJECTIVE Compare the 3-year clinical performance (wear as an additional parameter) of a nanocomposite and a microhybrid composite, versus ADA guidelines (2001) using direct (clinical/USPHS) and indirect (quantitative/3D laser scan and qualitative/SEM) methods, in parallel. METHODS 18 Filtek Supreme
페이스 북
페이지에 가입하세요

과학이 뒷받침하는 가장 완벽한 약초 데이터베이스

  • 55 개 언어로 작동
  • 과학이 뒷받침하는 약초 치료제
  • 이미지로 허브 인식
  • 인터랙티브 GPS지도-위치에 허브 태그 지정 (출시 예정)
  • 검색과 관련된 과학 출판물 읽기
  • 효과로 약초 검색
  • 관심사를 정리하고 뉴스 연구, 임상 실험 및 특허를 통해 최신 정보를 확인하세요.

증상이나 질병을 입력하고 도움이 될 수있는 약초에 대해 읽고 약초를 입력하고 사용되는 질병과 증상을 확인합니다.
* 모든 정보는 발표 된 과학 연구를 기반으로합니다.

Google Play badgeApp Store badge